Practical Guidance for the Use of Loteprednol Etabonate Ophthalmic Suspension 0.25% in the Management of Dry Eye Disease

References

• Farrand KF, Fridman M, Stillman I, Schaumberg DA. Prevalence of diagnosed dry eye disease in the United States among adults aged 18 years and older. Am J Ophthalmol. 2017;182:90–98. doi:10.1016/j.ajo.2017.06.033
   PubMed Web of Science ®Google Scholar
• Moss SE, Klein R, Klein BE. Long-term incidence of dry eye in an older population. Optom Vis Sci. 2008;85(8):668–674. doi:10.1097/OPX.0b013e318181a947
   PubMed Web of Science ®Google Scholar
• Schaumberg DA, Sullivan DA, Buring JE, Dana MR. Prevalence of dry eye syndrome among US women. Am J Ophthalmol. 2003;136(2):318–326. doi:10.1016/S0002-9394(03)00218-6
   PubMed Web of Science ®Google Scholar
• Miljanović B, Dana R, Sullivan DA, Schaumberg DA. Impact of dry eye syndrome on vision-related quality of life. Am J Ophthalmol. 2007;143(3):409–415. doi:10.1016/j.ajo.2006.11.060
   PubMed Web of Science ®Google Scholar
• Craig JP, Nichols KK, Akpek EK, et al. TFOS DEWS II definition and classification report. Ocul Surf. 2017;15(3):276–283. doi:10.1016/j.jtos.2017.05.008
   PubMed Web of Science ®Google Scholar
• Yamaguchi T. Inflammatory response in dry eye. Invest Ophthalmol Vis Sci. 2018;59(14):Des192–des199. doi:10.1167/iovs.17-23651
   PubMed Web of Science ®Google Scholar
• Bron AJ, de Paiva CS, Chauhan SK, et al. TFOS DEWS II pathophysiology report. Ocul Surf. 2017;15(3):438–510. doi:10.1016/j.jtos.2017.05.011
   PubMed Web of Science ®Google Scholar
• Stevenson W, Chauhan SK, Dana R. Dry eye disease: an immune-mediated ocular surface disorder. Arch Ophthalmol. 2012;130(1):90–100. doi:10.1001/archophthalmol.2011.364
   PubMedGoogle Scholar
• Iyer JV, Lee SY, Tong L. The dry eye disease activity log study. ScientificWorldJournal. 2012;2012:589875. doi:10.1100/2012/589875
   PubMed Web of Science ®Google Scholar
• Karakus S, Agrawal D, Hindman HB, Henrich C, Ramulu PY, Akpek EK. Effects of prolonged reading on dry eye. Ophthalmology. 2018;125(10):1500–1505. doi:10.1016/j.ophtha.2018.03.039
   PubMed Web of Science ®Google Scholar
• Yazici A, Sari ES, Sahin G, et al. Change in tear film characteristics in visual display terminal users. Eur J Ophthalmol. 2015;25(2):85–89. doi:10.5301/ejo.5000525
   PubMed Web of Science ®Google Scholar
• López-Miguel A, Tesón M, Martín-Montañez V, et al. Dry eye exacerbation in patients exposed to desiccating stress under controlled environmental conditions. Am J Ophthalmol. 2014;157(4):788–798.e782. doi:10.1016/j.ajo.2014.01.001
   PubMed Web of Science ®Google Scholar
• Tesón M, González-García MJ, López-Miguel A, et al. Influence of a controlled environment simulating an in-flight airplane cabin on dry eye disease. Invest Ophthalmol Vis Sci. 2013;54(3):2093–2099. doi:10.1167/iovs.12-11361
   PubMed Web of Science ®Google Scholar
• Jones L, Downie LE, Korb D, et al. TFOS DEWS II management and therapy report. Ocul Surf. 2017;15(3):575–628. doi:10.1016/j.jtos.2017.05.006
   PubMed Web of Science ®Google Scholar
• De Paiva CS, Corrales RM, Villarreal AL, et al. Corticosteroid and doxycycline suppress MMP-9 and inflammatory cytokine expression, MAPK activation in the corneal epithelium in experimental dry eye. Exp Eye Res. 2006;83(3):526–535. doi:10.1016/j.exer.2006.02.004
   PubMed Web of Science ®Google Scholar
• Beckman K, Katz J, Majmudar P, Rostov A. Loteprednol etabonate for the treatment of dry eye disease. J Ocul Pharmacol Ther. 2020;36(7):497–511. doi:10.1089/jop.2020.0014
   PubMed Web of Science ®Google Scholar
• Sheppard JD, Comstock TL, Cavet ME. Impact of the topical ophthalmic corticosteroid loteprednol etabonate on intraocular pressure. Adv Ther. 2016;33(4):532–552. doi:10.1007/s12325-016-0315-8
   PubMed Web of Science ®Google Scholar
• Sheppard JD, Donnenfeld ED, Holland EJ, et al. Effect of loteprednol etabonate 0.5% on initiation of dry eye treatment with topical cyclosporine 0.05%. Eye Contact Lens. 2014;40(5):289–296. doi:10.1097/ICL.0000000000000049
   PubMed Web of Science ®Google Scholar
• Pflugfelder SC, Maskin SL, Anderson B, et al. A randomized, double-masked, placebo-controlled, multicenter comparison of loteprednol etabonate ophthalmic suspension, 0.5%, and placebo for treatment of keratoconjunctivitis sicca in patients with delayed tear clearance. Am J Ophthalmol. 2004;138(3):444–457. doi:10.1016/j.ajo.2004.04.052
   PubMed Web of Science ®Google Scholar
• Gaudana R, Ananthula HK, Parenky A, Mitra AK. Ocular drug delivery. Aaps J. 2010;12(3):348–360. doi:10.1208/s12248-010-9183-3
   PubMed Web of Science ®Google Scholar
• Cholkar K, Patel SP, Vadlapudi AD, Mitra AK. Novel strategies for anterior segment ocular drug delivery. J Ocul Pharmacol Ther. 2013;29(2):106–123. doi:10.1089/jop.2012.0200
   PubMed Web of Science ®Google Scholar
• Lai SK, Wang YY, Hanes J. Mucus-penetrating nanoparticles for drug and gene delivery to mucosal tissues. Adv Drug Deliv Rev. 2009;61(2):158–171. doi:10.1016/j.addr.2008.11.002
   PubMed Web of Science ®Google Scholar
• Yang M, Lai SK, Wang YY, et al. Biodegradable nanoparticles composed entirely of safe materials that rapidly penetrate human mucus. Angew Chem Int Ed Engl. 2011;50(11):2597–2600. doi:10.1002/anie.201006849
   PubMed Web of Science ®Google Scholar
• Popov A. Mucus-penetrating particles and the role of ocular mucus as a barrier to micro- and nanosuspensions. J Ocul Pharmacol Ther. 2020;36(6):366–375. doi:10.1089/jop.2020.0022
   PubMed Web of Science ®Google Scholar
• Schopf L, Enlow E, Popov A, Bourassa J, Chen H. Ocular pharmacokinetics of a novel loteprednol etabonate 0.4% ophthalmic formulation. Ophthalmol Ther. 2014;3(1–2):63–72. doi:10.1007/s40123-014-0021-z
   PubMedGoogle Scholar
• Schopf LR, Popov AM, Enlow EM, et al. Topical ocular drug delivery to the back of the eye by mucus-penetrating particles. Transl Vis Sci Technol. 2015;4(3):11. doi:10.1167/tvst.4.3.11
   PubMed Web of Science ®Google Scholar
• Korenfeld M, Nichols KK, Goldberg D, et al. Safety of KPI-121 ophthalmic suspension 0.25% in patients with dry eye disease: a pooled analysis of 4 multicenter, randomized, vehicle-controlled studies. Cornea. 2021;40(5):564–570. doi:10.1097/ICO.0000000000002452
   PubMed Web of Science ®Google Scholar
• Kim T, Sall K, Holland EJ, Brazzell RK, Coultas S, Gupta PK. Safety and efficacy of twice daily administration of KPI-121 1% for ocular inflammation and pain following cataract surgery. Clin Ophthalmol. 2019;13:69–86. doi:10.2147/OPTH.S185800
   PubMed Web of Science ®Google Scholar
• Sacchetti M, Mantelli F, Lambiase A, Mastropasqua A, Merlo D, Bonini S. Systematic review of randomised clinical trials on topical ciclosporin A for the treatment of dry eye disease. Br J Ophthalmol. 2014;98(8):1016–1022. doi:10.1136/bjophthalmol-2013-304072
   PubMed Web of Science ®Google Scholar
• Goldberg DF, Malhotra RP, Schechter BA, Justice A, Weiss SL, Sheppard JD. A Phase 3, randomized, double-masked study of OTX-101 ophthalmic solution 0.09% in the treatment of dry eye disease. Ophthalmology. 2019;126(9):1230–1237. doi:10.1016/j.ophtha.2019.03.050
   PubMed Web of Science ®Google Scholar
• Hovanesian JA, Berdy GJ, Epitropoulos A, Holladay JT. Effect of cyclosporine 0.09% treatment on accuracy of preoperative biometry and higher order aberrations in dry eye patients undergoing cataract surgery. Clin Ophthalmol. 2021;15:3679–3686. doi:10.2147/OPTH.S325659
   PubMed Web of Science ®Google Scholar
• Donnenfeld ED, Perry HD, Nattis AS, Rosenberg ED. Lifitegrast for the treatment of dry eye disease in adults. Expert Opin Pharmacother. 2017;18(14):1517–1524. doi:10.1080/14656566.2017.1372748
   PubMed Web of Science ®Google Scholar
• Ervin AM, Law A, Pucker AD. Punctal occlusion for dry eye syndrome. Cochrane Database Syst Rev. 2017;6(6):Cd006775. doi:10.1002/14651858.CD006775.pub3
   PubMed Web of Science ®Google Scholar
• Gupta PK, Venkateswaran N. The role of KPI-121 0.25% in the treatment of dry eye disease: penetrating the mucus barrier to treat periodic flares. Ther Adv Ophthalmol. 2021;13:25158414211012797. doi:10.1177/25158414211012797
   Google Scholar
• Gupta PK, Drinkwater OJ, VanDusen KW, Brissette AR, Starr CE. Prevalence of ocular surface dysfunction in patients presenting for cataract surgery evaluation. J Cataract Refract Surg. 2018;44(9):1090–1096. doi:10.1016/j.jcrs.2018.06.026
   PubMed Web of Science ®Google Scholar